SWK (SWKH) 10-Q 8 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	8-May-15
Document and Entity Information [Abstract]
Entity Registrant Name	SWK Holdings Corporation
Document Type	10-Q
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		131,135,092
Entity Public Float		$0
Amendment Flag	FALSE
Entity Central Index Key	1089907
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

UNAUDITED_CONDENSED_CONSOLIDAT

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
ASSETS
Cash and cash equivalents	$59,487	$58,728
Accounts receivable	1,139	1,053
Prepaid expenses and other assets	168	32
Finance receivables	95,456	93,347
Marketable investments	6,349	4,849
Investment in unconsolidated entities	8,740	9,044
Deferred tax asset	18,600	20,106
Warrant assets	1,406	679
Debt issuance costs		381
Total assets	191,345	188,219
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable and accrued liabilities	1,545	864
Warrant liability	586	421
Total liabilities	2,131	1,285
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 250,000,000 shares authorized; 131,135,092 and 131,058,303 shares issued and outstanding at March 31, 2015, and December 31, 2014, respectively	131	131
Additional paid-in capital	4,432,551	4,432,364
Accumulated deficit	-4,248,172	-4,250,428
Total SWK Holdings Corporation stockholders' equity	184,510	182,067
Non-controlling interests in consolidated entities	4,704	4,867
Total stockholders' equity	189,214	186,934
Total liabilities and stockholders' equity	$191,345	$188,219

UNAUDITED_CONDENSED_CONSOLIDAT1

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	131,135,092	131,058,303
Common stock, shares outstanding	131,135,092	131,058,303

UNAUDITED_CONDENSED_CONSOLIDAT2

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (USD $)	3 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Revenues
Finance receivable interest income, including fees	$4,145	$2,031
Marketable investments interest income	90	91
Income related to investments in unconsolidated entities	1,551	1,503
Other	15	43
Total Revenues	5,801	3,668
Costs and expenses:
Interest expense	381	189
General and administrative	1,218	669
Total costs and expenses	1,599	858
Other income:
Unrealized net gain on derivatives	371	154
Income before provision for income tax	4,573	2,964
Provision for income tax	1,506	706
Consolidated net income	3,067	2,258
Net income attributable to non-controlling interests	811	801
Net income attributable to SWK Holdings Corporation Stockholders	$2,256	$1,457
Net income per share attributable to SWK Holdings Corporation Stockholders
Basic	$0.02	$0.04
Diluted	$0.02	$0.04
Weighted Average Shares
Basic	129,964,000	41,462,000
Diluted	130,046,000	41,530,000

UNAUDITED_CONDENSED_CONSOLIDAT3

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Statement of Comprehensive Income [Abstract]
Consolidated net income	$3,067	$2,258
Unrealized gains on investment in securities
Unrealized holding gains arising during period
Less: reclassification adjustment for gains included in net income
Total other comprehensive income
Comprehensive income	3,067	2,258
Comprehensive income attributable to non-controlling interests	811	801
Comprehensive income attributable to SWK Holdings Corporation Stockholders	$2,256	$1,457

UNAUDITED_CONDENSED_CONSOLIDAT4

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Consolidated net income	$3,067	$2,258
Adjustments to reconcile consolidated net income to net cash provided by operating activities:
Income from investments in unconsolidated entities	-1,551	-1,503
Deferred income taxes	1,506	706
Interest income in excess of cash collected	-33	-431
Loan discount amortization and fee accretion	-344	-72
Change in fair value of warrants	-371	-154
Stock-based compensation	197	76
Debt issuance cost amortization	381	35
Property and equipment depreciation	1
Changes in operating assets and liabilities:
Accounts receivable	-86	172
Prepaid expenses and other assets	-87	-273
Accounts payable and accrued liabilities	681	443
Net cash provided by operating activities	3,361	1,257
Cash flows from investing activities:
Net increase in finance receivables	-3,423	-11,975
Cash distributions from investments in unconsolidated entities	1,855	1,976
Purchases of property and equipment	-50
Net cash provided by (used in) investing activities	-1,618	-9,999
Cash flows from financing activities:
Proceeds from loan credit agreement		6,000
Costs of common stock issuance	-10
Distributions to non-controlling interests	-974	-1,055
Net cash provided by (used in) financing activities	-984	4,945
Net increase (decrease) in cash and cash equivalents	759	-3,797
Cash and cash equivalents at beginning of period	58,728	7,664
Cash and cash equivalents at end of period	59,487	58,728
Supplementary noncash flow activity:
Consideration (notes and preferred stock) received in connection with loan repayment	8,400
Warrants received in conjunction with purchase of financial receivables	$191	$99

SWK_Holdings_Corporation_and_S

SWK Holdings Corporation and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block [Abstract]
SWK Holdings Corporation and Summary of Significant Accounting Policies	Note 1. SWK Holdings Corporation and Summary of Significant Accounting Policies
	Nature of Operations
	SWK Holdings Corporation (the “Company,” “SWK,” “we,” “us,” or “our”) was incorporated in July 1996 in California and reincorporated in Delaware in September 1999. In July 2012, the Company commenced its strategy of building a specialty finance and asset management business. The Company’s strategy is to be a leading healthcare capital provider by offering sophisticated, customized financing solutions to a broad range of life science companies, institutions and inventors. The Company has initially focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. The Company has been deploying its assets to earn interest, fees, and other income pursuant to this strategy, and the Company continues to identify and review financing and similar opportunities on an ongoing basis.
	As of March 31, 2015, the Company had executed 14 transactions under its specialty finance strategy, funding approximately $124,000,000 in various financial products across the life science sector. The Company’s portfolio includes senior and subordinated debt backed by royalties and synthetic royalties paid by companies in the life science sector, purchased royalties generated by sales of life science products and related intellectual property and an unconsolidated equity investment in a company which retains the marketing authorization rights to a pharmaceutical product.
	The Company is headquartered in Dallas, Texas.
	Basis of Presentation
	The Company’s unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”).  The unaudited condensed consolidated financial statements include the accounts of all subsidiaries and affiliates in which the Company holds a controlling financial interest as of the financial statement date. Normally a controlling financial interest reflects ownership of a majority of the voting interests. The Company consolidates a variable interest entity (“VIE”) when it possesses both the power to direct the activities of the VIE that most significantly impact its economic performance and the Company is either obligated to absorb the losses that could potentially be significant to the VIE or the Company holds the right to receive benefits from the VIE that could potentially be significant to the VIE, after elimination of intercompany accounts and transactions.
	The Company owns interests in various partnerships and limited liability companies, or LLCs. The Company consolidates its investments in these partnerships or LLCs, where the Company, as the general partner or managing member, exercises effective control, even though the Company’s ownership may be less than 50%. The related governing agreements provide the Company with broad powers, and the other parties do not participate in the management of the entity and do not have the substantial ability to remove the Company. The Company has reviewed each of the underlying agreements to determine if it has effective control. If circumstances changed and it was determined this control did not exist, this investment would be recorded using the equity method of accounting. Although this would change individual line items within the Company’s condensed consolidated financial statements, it would have no effect on our net income and/or total stockholders’ equity attributable to the Company. The Company operates in one operating segment with a single management team that reports to the chief executive officer, who is the Company’s chief operating decision maker.
	Unaudited Interim Financial Information
	The unaudited condensed consolidated financial statements have been prepared by the Company and reflect all normal, recurring adjustments that, in the opinion of management, are necessary for a fair presentation of the interim financial information. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for any subsequent quarter or for the year ending December 31, 2015. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted under the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited condensed consolidated financial statements and notes included herein should be read in conjunction with the audited consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 27, 2015.
	Use of Estimates
	The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition, stock-based compensation, impairment of financing receivables and long-lived assets, valuation of warrants, income taxes and contingencies and litigation, among others.  Some of these judgments can be subjective and complex, and, consequently, actual results may differ from these estimates. The Company estimates often are based on complex judgments, probabilities and assumptions that it believes to be reasonable but that are inherently uncertain and unpredictable. For any given individual estimate or assumption made by the Company, there may also be other estimates or assumptions that are reasonable.
	The Company regularly evaluates its estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, the Company’s estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Market conditions, such as illiquid credit markets, volatile equity markets, and economic downturn, can increase the uncertainty already inherent in the Company’s estimates and assumptions. The Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our condensed consolidated financial statements on a prospective basis unless they are required to be treated retrospectively under the relevant accounting standard. It is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.
	Reclassification
	Certain amounts have been reclassified in the presentation of the financial statements as of December 31, 2014 and for the three months ended March 31, 2014 to be consistent with the presentation in the financial statements for the three months ended March 31, 2015. This reclassification had no impact on previously reported net loss, cash flow from operations or changes in stockholder deficit.
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606),” which is the new comprehensive revenue recognition standard that will supersede all existing revenue recognition guidance under U.S. GAAP. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to a customer in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The tentative revised effective date for this ASU is for annual and interim periods beginning on or after December 15, 2017, and early adoption will be permitted. Entities will have the option of using either a full retrospective approach or a modified approach to adopt the guidance in the ASU. The Company is currently evaluating the impact of adopting this guidance.
	In February 2015, the FASB issued ASU 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis,” which makes changes to both the variable interest model and voting interest model and eliminates the indefinite deferral of FASB Statement No. 167, included in ASU 2010-10, for certain investment funds. All reporting entities that hold a variable interest in other legal entities will need to re-evaluate their consolidation conclusions as well as disclosure requirements. This ASU is effective for annual periods beginning after December 15, 2015, and early adoption is permitted, including any interim period. The Company is currently evaluating the impact of adopting this guidance.
	In April 2015, the FASB issued ASU 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs,” which requires debt issuance costs be presented in the balance sheet as a direct deduction from the carrying value of the associated debt liability, and amortization of those costs should be reported as interest expense.
	This ASU is effective for financial statements issued for annual and interim periods beginning after December 15, 2015, and early adoption is permitted for financial statements that have not been previously issued. The new guidance should be applied on a retrospective basis for each period presented in the balance sheet. The Company is currently evaluating the impact of adopting this guidance.
	In April 2015, the FASB issued ASU 2015-05, “Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement,” which provides guidance about whether a cloud computing arrangement includes a software license. The customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2015, and early adoption is permitted. The Company is currently evaluating the impact of adopting this guidance.

Net_Income_per_Share

Net Income per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Net Income per Share	Note 2. Net Income per Share
	Basic net income per share is computed using the weighted average number of outstanding shares of common stock. Diluted net income per share is computed using the weighted average number of outstanding shares of common stock and, when dilutive, shares of common stock issuable upon exercise of options and warrants deemed outstanding using the treasury stock method.
	The following table shows the computation of basic and diluted earnings per share for the following (in thousands, except per share amounts):
		Three Months Ended
		31-Mar-15		31-Mar-14
	Numerator:
	Net income attributable to SWK Holdings Corporation Shareholders	$	2,256	$	1,457
	Denominator:
	Weighted-average shares outstanding		129,964		41,462
	Effect of dilutive securities		82		68
	Weighted-average diluted shares		130,046		41,530
	Basic earnings per share	$	0.02	$	0.04
	Diluted earnings per share	$	0.02	$	0.04
	For the three month period ended March 31, 2015, and 2014, outstanding stock options and warrants to purchase shares of common stock in an aggregate of approximately 4,175,000 and 4,175,000 shares, respectively, have been excluded from the calculation of diluted net income per share as all such securities were anti-dilutive.

Finance_Receivables

Finance Receivables	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block [Abstract]
Finance Receivables	Note 3. Finance Receivables
	Finance receivables are reported at their determined principal balances net of any unearned income, cumulative charge-offs and unamortized deferred fees and costs. Unearned income and deferred fees and costs are amortized to interest income based on all cash flows expected using the effective interest method.
	The carrying value of finance receivables are as follows (in thousands):
		31-Mar-15		31-Dec-14
	Portfolio
	Term Loans	$	82,645	$	80,450
	Royalty Purchases		12,811		12,897
	Total		95,456		93,347
	The Company originates finance receivables to companies primarily in the life sciences sector. This concentration of credit exposes the Company to a higher degree of risk associated with this sector.
	On a quarterly basis, the Company evaluates the carrying value of each finance receivable for impairment. Currently there are no finance receivables considered impaired and no corresponding allowance for credit losses for impaired loans.
	A term loan is considered to be impaired when, based on current information and events, it is determined that the Company will not be able to collect the amounts due according to the loan contract, including scheduled interest payments. This evaluation is generally based on delinquency information, an assessment of the borrower’s financial condition and the adequacy of collateral, if any. The Company would generally place term loans on nonaccrual status when the full and timely collection of interest or principal becomes uncertain and they are 90 days past due for interest or principal, unless the term loan is both well-secured and in the process of collection. When placed on nonaccrual, the Company would reverse any accrued unpaid interest receivable against interest income and amortization of any net deferred fees is suspended. Generally, the Company would return a term loan to accrual status when all delinquent interest and principal become current under the terms of the credit agreement and collectability of remaining principal and interest is no longer doubtful. In certain circumstances, the Company may place a finance receivable on nonaccrual status but conclude it is not impaired.
	Receivables associated with royalty stream purchases would be considered to be impaired when it is probable that the Company will be unable to collect the book value of the remaining investment based upon adverse changes in the estimated underlying royalty stream.
	When the Company identifies a finance receivable as impaired, it measures the impairment based on the present value of expected future cash flows, discounted at the receivable’s effective interest rate. If it is determined that the value of an impaired receivable is less than the recorded investment, the Company would recognize impairment with a charge to the allowance for credit losses. When the value of the impaired receivable is calculated by discounting expected cash flows, interest income would be recognized using the receivable’s effective interest rate over the remaining life of the receivable.
	The Company would individually develop the allowance for credit losses for any identified impaired loans if any existed. In developing the allowance for credit losses, the Company would consider, among other things, the following credit quality indicators:
	• business characteristics and financial conditions of obligors;
	• current economic conditions and trends;
	• actual charge-off experience;
	• current delinquency levels;
	• value of underlying collateral and guarantees;
	• regulatory environment; and
	• any other relevant factors predicting investment recovery.
	Non-Accrual Loan
	The Company had one non-accrual loan at March 31, 2015, for approximately $6,650,000. The Company measured the loan for impairment as of March 31, 2015, by comparing the outstanding loan balance to the fair market value of the collateral and determined that the fair market value of the collateral exceeded the outstanding balance. As a result, the Company was not required to record any impairment charge on this loan as of March 31, 2015. As of March 31, 2014, the Company did not have any non-performing assets.

Marketable_Investments

Marketable Investments	3 Months Ended
	Mar. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Marketable Investments	Note 4. Marketable Investments
	Investment in securities at March 31, 2015, and December 31, 2014, consist of the following (in thousands):
		March 31,		December 31,
		2015		2014
	Fixed income	$	3,119	$	3,119
	Equity securities		3,230		1,730
	Total	$	6,349	$	4,849
	The amortized cost basis amounts, gross unrealized holding gains, gross unrealized holding losses and fair values of available-for-sale securities as of March 31, 2015, and December 31, 2014, are as follows (in thousands):
		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Loss		Fair Value
	Available for sale securities:
	Corporate debt securities	$	3,119	$	—	$	—	$	3,119
		$	3,119	$	—	$	—	$	3,119
	During the three months ended March 31, 2015, and the year ended December 31, 2014, the Company had no sales of available-for-sale securities and no securities have been considered impaired.

Variable_Interest_Entities

Variable Interest Entities	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block [Abstract]
Variable Interest Entities	Note 5. Variable Interest Entities
	The Company consolidates the activities of VIEs of which we are the primary beneficiary. The primary beneficiary of a VIE is the variable interest holder possessing a controlling financial interest through (i) its power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (ii) its obligation to absorb losses or its right to receive benefits from the VIE that could potentially be significant to the VIE. In order to determine whether the Company owns a variable interest in a VIE, the Company performs qualitative analysis of the entity’s design, organizational structure, primary decision makers and relevant agreements.
	Consolidated VIE
	SWK HP Holdings LP (“SWK HP”)
	SWK HP was formed in December 2012 to acquire a limited partnership interest in Holmdel Pharmaceuticals LP (“Holmdel”).   Holmdel acquired the U.S. marketing authorization rights to a beta blocker pharmaceutical product indicated for the treatment of hypertension for a total purchase price of $13,000,000. The Company, through its wholly owned subsidiary SWK Holdings GP LLC (“SWK Holdings GP”) acquired a direct general partnership interest in SWK HP, which in turn acquired a limited partnership interest in Holmdel. The total investment in SWK HP of $13,000,000 included $6,000,000 provided by SWK Holdings GP and $7,000,000 provided by non-controlling interests.   Subject to customary limited partner protections afforded the investors by the terms of the limited partnership agreement, the Company maintains voting and managerial control of SWK HP and therefore includes it in its consolidated financial statements.
	SWK HP is considered a VIE due to the lack of voting or similar decision-making rights by its equity holders regarding activities that have a significant effect on the economic success of the partnership. The Company’s ownership in SWK HP constitutes variable interests. The Company has determined that it is the primary beneficiary of SWK HP as (i) the Company has the power to direct the activities that most significantly impact the economic performance of SWK HP via its obligations to perform under the partnership agreement, and (ii) the Company has the right to receive residual returns that could potentially be significant to SWK HP. As a result, the Company consolidates SWK HP in its financial statements and the limited partner interests of SWK HP owned by third parties are reflected as a non-controlling interest in the Company’s unaudited condensed consolidated balance sheets.
	Unconsolidated VIEs
	Holmdel
	SWK HP has significant influence over the decisions made by Holmdel. SWK HP will receive quarterly distributions of cash flow generated by the pharmaceutical product according to a tiered scale that is subject to certain cash on cash returns received by SWK HP. Until SWK HP received a 1x cash on cash return on its interest in Holmdel, which occurred in February 2015, SWK HP received approximately 84% of the pharmaceutical product’s cash flow. As the cash on cash multiple received by SWK HP Holdings LP increases, SWK HP’s interest in the cash flow generated by the pharmaceutical product decreases, but in no instance will it decline below 39%. Holmdel is considered a VIE because SWK HP’s control over the partnership is disproportionate to its economic interest. This VIE remains unconsolidated as the power to direct the activities of the partnership is not held by the Company. The Company is using the equity method to account for this investment.  SWK HP’s current ownership in Holmdel approximates 70%.  The Company accounts for its interest in the entity based on the timing of quarterly distributions, which are paid on a quarter lag basis. For the three months ended March 31, 2015, and 2014, the Company recognized $1,551,000 and $1,503,000, respectively, of equity method gains. The amount of equity method gains attributable to the non-controlling interests in SWK HP were $811,000 and $801,000 for the three months ended March 31, 2015, and 2014, respectively.
	In addition, SWK HP received cash distributions totaling $1,855,000 during the three months ended March 31, 2015, of which $974,000 was subsequently paid to holders of the non-controlling interests in SWK HP. Changes in the carrying amount of the Company’s investment in Holmdel for the three months ended March 31, 2015, are as follows (in thousands):
	Balance at December 31, 2014		$	9,044
	Add: Income from investments in unconsolidated entities			1,551
	Less: Cash distribution on investments in unconsolidated entities			(1,855	)
	Balance at March 31, 2015		$	8,740
	The following table provides the financial statement information related to Holmdel for the comparative periods which SWK HP has reflected its share of Holmdel income in the Company’s consolidated statements of income:
					As of March 31,			Three months ended		Three months ended
					2015			31-Mar-15		31-Mar-14
					(in millions)			(in millions)		(in millions)
		Assets			$	11.9	Revenue	$	2.4	$	2.4
		Liabilities			$	2.4	Expenses	$	0.4	$	0.6
		Equity			$	9.5	Net income	$	2	$	1.8

Loan_Credit_Agreement_with_Rel

Loan Credit Agreement with Related Party	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Loan Credit Agreement with Related Party	Note 6. Loan Credit Agreement with Related Party
	On September 6, 2013, the Company entered into a credit facility with Double Black Diamond, L.P. (the “Lender”), an affiliate of, Carlson Capital, L.P. (“Carlson”). Funds affiliated with Carlson (collectively, the “Stockholder”) are holders of a majority of the Company’s common stock. The credit facility provides financing for the Company, primarily for the purchase of eligible investments. The facility matures on September 6, 2017, and provides that the loan shall accrue interest at the LIBOR rate plus a 6.50% margin. The principal is repayable in full at maturity. The facility works as a delayed draw credit facility with the Company having the ability to draw down, as necessary, over the first 18 months (the “Draw Period”) up to $30,000,000, based on certain conditions. The credit facility provided for an initial $15,000,000 to be available at closing. The Draw Period expired on March 6, 2015, and as a result, as of March 31, 2015, the Company has no availability remaining on the facility. The Lender has received a security interest in basically all assets of the Company as collateral for the facility. In conjunction with the credit facility, the Company issued warrants to the Lender for 1,000,000 shares of the Company’s common stock at a strike price of $1.3875. The warrants have a price dilution mechanism that was triggered by the price that shares were sold in the Rights Offering in November 2014, and as a result, the strike price of the warrants was reduced to $1.348. In connection with the credit agreement, the Company, the Lender,the Stockholder and certain of the Stockholder’s affiliates, entered into a Voting Rights Agreement restricting the Stockholder’s and such affiliates’ voting rights under certain circumstances and providing the Stockholder and such affiliates a right of first offer on certain future share issuances, which Voting Rights Agreement was terminated on August 18, 2014, in connection with the sale of shares of common stock to the Stockholder.
	Due to certain provisions within the warrant agreement, the warrants meet the definition of a derivative and do not qualify for a scope exception as it is not considered indexed in the Company’s stock. As such, the warrants with a value of $586,000 and $421,000 at March 31, 2015, and December 31, 2014, respectively, are reflected as a warrant liability in the unaudited condensed consolidated balance sheets. An unrealized loss of $165,000 and an unrealized gain of $42,000 were included in interest and other income (expense) in the unaudited condensed consolidated statements of income for the three months ended March 31, 2015, and 2014, respectively. The Company determined the fair value using the Black-Scholes option pricing model with the following assumptions:
		March 31,			December 31,
		2015			2014
	Dividend rate		0	%		0	%
	Risk-free rate		1.4	%		1.7	%
	Expected life (years)		5.4			5.7
	Expected volatility		32.6	%		32.7	%
	During the three months ended March 31, 2015, the Company recognized interest expense totaling $381,000 consisting of debt issuance cost amortization. During the three months ended March 31, 2014, the Company recognized interest expense totaling $189,000, which included $153,000 interest due the lender and $36,000 of debt issuance cost amortization.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block [Abstract]
Stockholders' Equity	Note 7. Stockholders’ Equity
	Stock Compensation Plans
	The Company’s 1999 Stock Incentive Plan (the “1999 Stock Incentive Plan”), as successor to the 1997 Stock Option Plan (the “1997 Stock Option Plan”), provided for options to purchase shares of the Company’s common stock to be granted to employees, independent contractors, officers, and directors. The plan expired in July 2009. As a result of the termination of all employees on December 31, 2009, the stock options held by employees were cancelled on March 31, 2010.  The only remaining options outstanding as of March 31, 2014, under the 1999 Stock Incentive Plan are those held by some of the Company’s current directors.
	The Company’s 2010 Stock Incentive Plan (the “2010 Stock Incentive Plan”) provides for options, restricted stock, and other customary forms of equity to be granted to the Company’s directors, officers, employees, and independent contractors. All forms of equity incentive compensation are granted at the discretion of the Company’s Board of Directors (the “Board”) and have a term not greater than 10 years from the date of grant.
	There were no options exercised in the three months ended March 31, 2015 or 2014.
	The following table summarizes activities under option plans for the indicated periods:
			Options Outstanding
			Number of				Weighted			Weighted				Aggregate
			Shares				Average			Average				Intrinsic
							Exercise			Remaining Contractual				Value
							Price			Term
										(in years)
	Balances, December 31, 2014			3,670,000			$	1.2			8.3			$	1,109,200
	Options cancelled and retired			—				—
	Options exercised			—				—
	Options granted			—				—
	Balances, March 31, 2015			3,670,000				1.2			8.1				1,569,400
	Options vested and exercisable and expected to be vested and exercisable at March 31, 2015			3,380,000			$	1.2			8.1			$	1,569,400
	Options vested and exercisable at March 31, 2015			545,000			$	1.36			5.8			$	305,650
	At March 31, 2015, there were no options available for grant under the 1999 Stock Incentive Plan, and the Company had no total unrecognized stock-based compensation expense under this Plan.  At March 31, 2015, there were 2.7 million shares reserved for equity awards under the 2010 Stock Incentive Plan and the Company had approximately $0.6 million of total unrecognized stock option expense, net of estimated forfeitures, which will be recognized over the weighted average remaining period of 2 years.
	The following table summarizes significant ranges of outstanding and exercisable options as of March 31, 2015:
					Options Outstanding, Vested and Exercisable
	Exercise Prices					Number			Weighted			Weighted				Number	Weighted Average Exercise Price Per Share
						Outstanding			Average			Average				Exercisable
									Remaining			Exercise
									Contractual			Price Per
									Life (in Years)			Share
	$	0.7				20,000			4.3			$	0.7			20,000	$	0.7
		0.83				1,500,000			7.1				0.83			375,000		0.83
		1.24				20,000			3.3				1.24			20,000		1.24
		1.37				2,000,000			9.4				1.37			—		1.37
		2.67				20,000			2.3				2.67			20,000		2.67
		2.95				90,000			1.45				2.95			90,000		2.95
		3.5				20,000			1.9				3.5			20,000		3.5
	Total					3,670,000			8.1			$	1.2			545,000	$	1.36
	Employee stock-based compensation expense recognized for time-vesting options for the three months ended March 31, 2015, and 2014, uses the Black-Scholes option pricing model for estimating the fair value of options granted under the Company’s equity incentive plans. Risk-free interest rates for the options were taken from the Daily Federal Yield Curve Rates on the grant dates for the expected life of the options as published by the Federal Reserve. The expected volatility was based upon historical data and other relevant factors such as the Company’s changes in historical volatility and its capital structure, in addition to mean reversion. Employee stock-based compensation expense recognized for market performance-vesting options uses a binomial lattice model for estimating the fair value of options granted under the Company’s equity incentive plans.
	In calculating the expected life of stock options, the Company determines the amount of time from grant date to exercise date for exercised options and adjusts this number for the expected time to exercise for unexercised options. The expected time to exercise for unexercised options is calculated from grant as the midpoint between the expiration date of the option and the later of the measurement date or the vesting date. In developing the expected life assumption, all amounts of time are weighted by the number of underlying options.
	The following table summarizes restricted stock activities under the equity incentive plans for the indicated periods:
			Restricted Shares Outstanding
			Number of Shares				Weighted Average Grant Date Fair Value
	Balances, December 31, 2014			1,125,500			$	0.31
	Shares cancelled and forfeited			—				—
	Shares vested			—				—
	Shares granted			—				—
	Balances, March 31, 2015			1,125,000			$	0.31
	For restricted stock granted in 2014 and 2013 under the 2010 Stock Incentive Plan, the Company recognizes compensation expense in accordance with the fair value of such stock as determined on the grant date, amortized over the applicable derived service period using the graded amortization method. The fair value and derived service period of awards with market performance vesting was calculated using a lattice model and included adjustments to the fair value of the Company’s common stock resulting from the vesting conditions being based on the underlying stock price. Restricted shares of 1,125,000 are included in the Company’s shares outstanding as of March 31, 2015, but are not included in the computation of basic income per share as the shares are not yet earned by the recipients. The Company had no unrecognized stock based compensation expense, net of estimated forfeitures, related to restricted shares as of March 31, 2015.
	During the three months ending March 31, 2015, the Board approved the following grants as compensation for Board services: (i) a grant of 33,660 shares of common stock as the pro-rated director compensation for the non-employee directors appointed on September 6, 2014; (ii) a grant 10,000 shares to each non-employee directors for services as a director for the period January 1, 2015 to March 31, 2015; and (iii) a grant of 32,595 shares of common stock in lieu of cash payments to the non-employee directors upon the voluntary election of such directors. The Company recorded approximately $107,000 in board compensation expense relating to the quarterly grant,
	The stock-based compensation expense recognized by the Company for the three months ended March 31, 2015, and 2014 was $90,000 and $76,000, respectively.
	Non-controlling Interests
	As discussed in Note 5, SWK HP has a limited partnership interest in Holmdel.  Changes in the carrying amount of the non-controlling interest in the unaudited condensed consolidated balance sheet for the three months ended March 31, 2015, are as follows (in thousands):
	Balance at December 31, 2014		$	4,867
	Add: Income attributable to non-controlling interests			811
	Less: Cash distribution to non-controlling interests			(974	)
	Balance at March 31, 2015		$	4,704

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Note 8. Fair Value Measurements
	The Company measures and reports certain financial and non-financial assets and liabilities on a fair value basis. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). GAAP specifies a three-level hierarchy that is used when measuring and disclosing fair value. The fair value hierarchy gives the highest priority to quoted prices available in active markets (i.e., observable inputs) and the lowest priority to data lacking transparency (i.e., unobservable inputs). An instrument’s categorization within the fair value hierarchy is based on the lowest level of significant input to its valuation. The following is a description of the three hierarchy levels.
	Level 1	Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Active markets are considered to be those in which transactions for the assets or liabilities occur in sufficient frequency and volume to provide pricing information on an ongoing basis.
	Level 2	Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability. This category includes quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in inactive markets.
	Level 3	Unobservable inputs are not corroborated by market data. This category is comprised of financial and non-financial assets and liabilities whose fair value is estimated based on internally developed models or methodologies using significant inputs that are generally less readily observable from objective sources.
	Transfers into or out of any hierarchy level are recognized at the end of the reporting period in which the transfers occurred. There were no transfers between any levels during the three months ended March 31, 2015, and 2014.
	The fair value of equity method investments is not readily available nor have we estimated the fair value of these investments and disclosure is not required. The Company is not aware of any identified events or changes in circumstances that would have a significant adverse effect on the carrying value of any of our equity method investments included in our unaudited condensed consolidated balance sheets at March 31, 2015, or December 31, 2014.
	Following are descriptions of the valuation methodologies used to measure material assets and liabilities at fair value and details of the valuation models, key inputs to those models and significant assumptions utilized.
	Finance Receivables
	The fair values of finance receivables are estimated using discounted cash flow analyses, using market rates at the balance sheet date that reflect the credit and interest rate-risk inherent in the finance receivables. Projected future cash flows are calculated based upon contractual maturity or call dates, projected repayments and prepayments of principal. These receivables are classified as Level 3. Finance receivables are not measured at fair value on a recurring basis, but estimates of fair value are reflected below.
	Marketable Investments and Warrants
	Marketable Investments
	If active market prices are available, fair value measurement is based on quoted active market prices and, accordingly, these securities would be classified as Level 1. If active market prices are not available, fair value measurement is based on observable inputs other than quoted prices included within Level 1, such as prices for similar assets or broker quotes utilizing observable inputs, and accordingly these securities would be classified as Level 2. If market prices are not available and there are no observable inputs, then fair value would be estimated by using valuation models including discounted cash flow methodologies, commonly used option-pricing models and broker quotes. Such securities would be classified as Level 3, if the valuation models and broker quotes are based on inputs that are unobservable in the market. If fair value is based on broker quotes, the Company checks the validity of received prices based on comparison to prices of other similar assets and market data such as relevant bench mark indices. Available-for-sale securities are measured at fair value on a recurring basis, while securities with no readily available fair market value are not, but estimates of fair value are reflected below.
	Derivative securities
	For exchange-traded derivatives, fair value is based on quoted market prices, and accordingly, would be classified as Level 1. For non-exchange traded derivatives, fair value is based on option pricing models and are classified as Level 3.
	The following table presents financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2015 (in thousands):
			Total Carrying Value in Consolidated Balance Sheet			Quoted prices			Significant		Significant
						in active			Other		Unobservable
						markets for			observable		inputs
						identical assets			inputs		(Level 3)
						or liabilities			(Level 2)
						(Level 1)
	Financial Assets:
	Warrant assets		$	1,406		$	—		$	—	$	1,406
	Available-for-sale securities			3,119			—			—		3,119
	Financial Liabilities:
	Warrant liability		$	586		$	—		$	—	$	586
	The following table presents financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2014 (in thousands):
			Total Carrying Value in Consolidated Balance Sheet			Quoted prices			Significant		Significant
						in active			other		unobservable
						markets for			observable		inputs
						identical assets			inputs		(Level 3)
						or liabilities			(Level 2)
						(Level 1)
	Financial Assets:
	Warrant assets		$	679		$	—		$	—	$	679
	Available-for-sale securities			3,119			—			—		3,119
	Financial Liabilities:
	Warrant liability		$	421		$	—		$	—	$	421
	The changes on the value of the warrant assets during the three months ended March 31, 2015, were as follows (in thousands):
	Balance at December 31, 2014		$	679
	Issuances			191
	Change in fair value			536
	Balance at March 31, 2015		$	1,406
	The Company holds warrants issued to the Company in conjunction with certain term loan investments. These warrants meet the definition of a derivative and are included in the unaudited condensed consolidated balance sheets. The fair values for warrants outstanding, that have a readily determinable value, are measured using the Black-Scholes option pricing model. The following weighted average assumptions were used in the models to determine fair value:
			31-Mar-15			31-Dec-14
	Dividend rate			0	%		0	%
	Risk-free rate			1.4	%		1.8	%
	Expected life (years)			5.3			5.4
	Expected volatility			93.9	%		94.3	%
	The changes on the value of the warrant liability during the three months ended March 31, 2015, were as follows (in thousands):
	Balance at December 31, 2014		$	421
	Issuances			—
	Change in fair value			165
	Balance at March 31, 2015		$	586
	For assets and liabilities measured on a non-recurring basis during the year, accounting guidance requires quantitative disclosures about the fair value measurements separately for each major category. There were no remeasured assets or liabilities at fair value on a non-recurring basis during the three months ended March 31, 2015, and 2014.
	The following information is provided to help readers gain an understanding of the relationship between amounts reported in the accompanying consolidated financial statements and the related market or fair value. The disclosures include financial instruments and derivative financial instruments, other than investment in affiliates (in thousands):
	31-Mar-15		Carry			Fair			Level 1		Level 2		Level 3
			Value			Value
	Financial Assets
	Cash and cash equivalents		$	59,487		$	59,487		$	59,487	$	—	$	—
	Finance receivables			95,456			95,456			—		—		95,456
	Marketable investments			6,349			6,349			—		—		6,349
	Other assets			1,406			1,406			—		—		1,406
Financial Liabilities
Warrant liability		$	586		$	586		$	—	$	—	$	586
31-Dec-14		Carry			Fair			Level 1		Level 2		Level 3
		Value			Value
Financial Assets
Cash and cash equivalents		$	58,728		$	58,728		$	58,728	$	—	$
Finance receivables			93,347			93,347			—		—		93,347
Marketable investments			4,849			4,849			—		—		4,849
Other assets			679			679			—		—		679
Financial Liabilities
Warrant liability		$	421		$	421		$	—	$	—	$	421

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 9. Income Taxes
	The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense. The Company had no unrecognized tax benefits as of March 31, 2015, and December 31, 2014.
	The Company will continue to assess the need for a valuation allowance on the deferred tax assets by evaluating both positive and negative evidence that may exist on a quarterly basis. Any adjustment to the deferred tax asset valuation allowance would be recorded in the unaudited condensed consolidated statement of income for the period that the adjustment is determined to be required.
	Deferred tax assets consist of the following (in thousands):
		March 31,			December 31,
		2015			2014
	Deferred tax assets
	Credit carryforward	$	2,660		$	2,660
	Stock based compensation		470			470
	Other		271			271
	Net operating losses		145,007			146,513
	Gross deferred tax assets		148,408			149,914
	Valuation allowance		(129,808	)		(129,808	)
	Net deferred tax assets	$	18,600		$	20,106
	The Tax Reform Act of 1986 limits the use of net operating loss and tax credit carryforwards in certain situations where stock ownership changes occur. In the event the Company has had a change in ownership, the future utilization of the Company’s net operating loss and tax credit carryforwards could be limited.
	A portion of deferred tax assets relating to net operating loss carryforwards (“NOLs”), pertains to NOLs resulting from tax deductions upon the exercise of employee stock options of approximately $1,900,000. When recognized, the tax benefit of these loss carryforwards will be accounted for as a credit to additional paid-in capital rather than a reduction of the income tax expense.
	As of December 31, 2014, the Company had net operating loss carryforwards for federal income tax purposes of approximately $421,000,000. The federal net operating loss carryforwards, if not offset against future income, will expire by 2032, with the majority of such NOLs expiring by 2021.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 10. Subsequent Events
	During April 2015, the Company entered into two new senior secured credit agreements for a total commitment of $12,500,000, of which $10,000,000 funded upon close. In conjunction with one of the credit agreements, the Company was issued a warrant to purchase 8,152,174 shares of common stock with an exercise price of $0.46 per share that may be exercised at any time prior to April 17, 2022. In addition, on April 6, 2015 the Company amended the credit agreement of one of its partner companies to allow the draw of the remaining $2.0 million available under the facility, of which $1.0 million was funded by the Company and $1.0 million by an unaffiliated third party. In connection with the amendment, the Company received warrants to purchase 1,351,351 shares of common stock. In addition, on May 7, 2015, SWK signed a commitment letter obligating the Company to fund up to $12 million in a loan transaction subject to the potential borrower fulfilling certain obligations.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations
	SWK Holdings Corporation (the “Company,” “SWK,” “we,” “us,” or “our”) was incorporated in July 1996 in California and reincorporated in Delaware in September 1999. In July 2012, the Company commenced its strategy of building a specialty finance and asset management business. The Company’s strategy is to be a leading healthcare capital provider by offering sophisticated, customized financing solutions to a broad range of life science companies, institutions and inventors. The Company has initially focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. The Company has been deploying its assets to earn interest, fees, and other income pursuant to this strategy, and the Company continues to identify and review financing and similar opportunities on an ongoing basis.
	As of March 31, 2015, the Company had executed 14 transactions under its specialty finance strategy, funding approximately $124,000,000 in various financial products across the life science sector. The Company’s portfolio includes senior and subordinated debt backed by royalties and synthetic royalties paid by companies in the life science sector, purchased royalties generated by sales of life science products and related intellectual property and an unconsolidated equity investment in a company which retains the marketing authorization rights to a pharmaceutical product.
	The Company is headquartered in Dallas, Texas.
Basis of Presentation	Basis of Presentation
	The Company’s unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”).  The unaudited condensed consolidated financial statements include the accounts of all subsidiaries and affiliates in which the Company holds a controlling financial interest as of the financial statement date. Normally a controlling financial interest reflects ownership of a majority of the voting interests. The Company consolidates a variable interest entity (“VIE”) when it possesses both the power to direct the activities of the VIE that most significantly impact its economic performance and the Company is either obligated to absorb the losses that could potentially be significant to the VIE or the Company holds the right to receive benefits from the VIE that could potentially be significant to the VIE, after elimination of intercompany accounts and transactions.
	The Company owns interests in various partnerships and limited liability companies, or LLCs. The Company consolidates its investments in these partnerships or LLCs, where the Company, as the general partner or managing member, exercises effective control, even though the Company’s ownership may be less than 50%. The related governing agreements provide the Company with broad powers, and the other parties do not participate in the management of the entity and do not have the substantial ability to remove the Company. The Company has reviewed each of the underlying agreements to determine if it has effective control. If circumstances changed and it was determined this control did not exist, this investment would be recorded using the equity method of accounting. Although this would change individual line items within the Company’s condensed consolidated financial statements, it would have no effect on our net income and/or total stockholders’ equity attributable to the Company. The Company operates in one operating segment with a single management team that reports to the chief executive officer, who is the Company’s chief operating decision maker.
Unaudited Interim Financial Information	Unaudited Interim Financial Information
	The unaudited condensed consolidated financial statements have been prepared by the Company and reflect all normal, recurring adjustments that, in the opinion of management, are necessary for a fair presentation of the interim financial information. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for any subsequent quarter or for the year ending December 31, 2015. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted under the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited condensed consolidated financial statements and notes included herein should be read in conjunction with the audited consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 27, 2015.
Use of Estimates	Use of Estimates
	The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition, stock-based compensation, impairment of financing receivables and long-lived assets, valuation of warrants, income taxes and contingencies and litigation, among others.  Some of these judgments can be subjective and complex, and, consequently, actual results may differ from these estimates. The Company estimates often are based on complex judgments, probabilities and assumptions that it believes to be reasonable but that are inherently uncertain and unpredictable. For any given individual estimate or assumption made by the Company, there may also be other estimates or assumptions that are reasonable.
	The Company regularly evaluates its estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, the Company’s estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Market conditions, such as illiquid credit markets, volatile equity markets, and economic downturn, can increase the uncertainty already inherent in the Company’s estimates and assumptions. The Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our condensed consolidated financial statements on a prospective basis unless they are required to be treated retrospectively under the relevant accounting standard. It is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.
Reclassification	Reclassification
	Certain amounts have been reclassified in the presentation of the financial statements as of December 31, 2014 and for the three months ended March 31, 2014 to be consistent with the presentation in the financial statements for the three months ended March 31, 2015. This reclassification had no impact on previously reported net loss, cash flow from operations or changes in stockholder deficit.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606),” which is the new comprehensive revenue recognition standard that will supersede all existing revenue recognition guidance under U.S. GAAP. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to a customer in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The tentative revised effective date for this ASU is for annual and interim periods beginning on or after December 15, 2017, and early adoption will be permitted. Entities will have the option of using either a full retrospective approach or a modified approach to adopt the guidance in the ASU. The Company is currently evaluating the impact of adopting this guidance.
	In February 2015, the FASB issued ASU 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis,” which makes changes to both the variable interest model and voting interest model and eliminates the indefinite deferral of FASB Statement No. 167, included in ASU 2010-10, for certain investment funds. All reporting entities that hold a variable interest in other legal entities will need to re-evaluate their consolidation conclusions as well as disclosure requirements. This ASU is effective for annual periods beginning after December 15, 2015, and early adoption is permitted, including any interim period. The Company is currently evaluating the impact of adopting this guidance.
	In April 2015, the FASB issued ASU 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs,” which requires debt issuance costs be presented in the balance sheet as a direct deduction from the carrying value of the associated debt liability, and amortization of those costs should be reported as interest expense.
	This ASU is effective for financial statements issued for annual and interim periods beginning after December 15, 2015, and early adoption is permitted for financial statements that have not been previously issued. The new guidance should be applied on a retrospective basis for each period presented in the balance sheet. The Company is currently evaluating the impact of adopting this guidance.
	In April 2015, the FASB issued ASU 2015-05, “Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement,” which provides guidance about whether a cloud computing arrangement includes a software license. The customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2015, and early adoption is permitted. The Company is currently evaluating the impact of adopting this guidance.

Net_Income_per_Share_Tables

Net Income per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table shows the computation of basic and diluted earnings per share for the following (in thousands, except per share amounts):
		Three Months Ended
		31-Mar-15		31-Mar-14
	Numerator:
	Net income attributable to SWK Holdings Corporation Shareholders	$	2,256	$	1,457
	Denominator:
	Weighted-average shares outstanding		129,964		41,462
	Effect of dilutive securities		82		68
	Weighted-average diluted shares		130,046		41,530
	Basic earnings per share	$	0.02	$	0.04
	Diluted earnings per share	$	0.02	$	0.04

Finance_Receivables_Tables

Finance Receivables (Tables)	3 Months Ended
	Mar. 31, 2015
Receivables [Abstract]
Schedule of carrying value of finance receivables [Table Text Block]	The carrying value of finance receivables are as follows (in thousands):
		31-Mar-15		31-Dec-14
	Portfolio
	Term Loans	$	82,645	$	80,450
	Royalty Purchases		12,811		12,897
	Total		95,456		93,347

Marketable_Investments_Tables

Marketable Investments (Tables)	3 Months Ended
	Mar. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Schedule of Marketable Investments	Investment in securities at March 31, 2015, and December 31, 2014, consist of the following (in thousands):
		March 31,		December 31,
		2015		2014
	Fixed income	$	3,119	$	3,119
	Equity securities		3,230		1,730
	Total	$	6,349	$	4,849
Schedule of Available-for-sale Securities Reconciliation [Table Text Block]	The amortized cost basis amounts, gross unrealized holding gains, gross unrealized holding losses and fair values of available-for-sale securities as of March 31, 2015, and December 31, 2014, are as follows (in thousands):
		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Loss		Fair Value
	Available for sale securities:
	Corporate debt securities	$	3,119	$	—	$	—	$	3,119
		$	3,119	$	—	$	—	$	3,119

Variable_Interest_Entities_Tab

Variable Interest Entities (Tables)	3 Months Ended
	Mar. 31, 2015
Variable Interest Entities [Abstract]
Schedule of changes in the carrying amount of equity investment table text block	Changes in the carrying amount of the Company’s investment in Holmdel for the three months ended March 31, 2015, are as follows (in thousands):
	Balance at December 31, 2014		$	9,044
	Add: Income from investments in unconsolidated entities			1,551
	Less: Cash distribution on investments in unconsolidated entities			(1,855	)
	Balance at March 31, 2015		$	8,740
Equity Method Investments [Table Text Block]	The following table provides the financial statement information related to Holmdel for the comparative periods which SWK HP has reflected its share of Holmdel income in the Company’s consolidated statements of income:
					As of March 31,			Three months ended		Three months ended
					2015			31-Mar-15		31-Mar-14
					(in millions)			(in millions)		(in millions)
		Assets			$	11.9	Revenue	$	2.4	$	2.4
		Liabilities			$	2.4	Expenses	$	0.4	$	0.6
		Equity			$	9.5	Net income	$	2	$	1.8

Loan_Credit_Agreement_Tables

Loan Credit Agreement (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Schedule of Assumptions Used [Table Text Block]	The Company determined the fair value using the Black-Scholes option pricing model with the following assumptions:
		March 31,			December 31,
		2015			2014
	Dividend rate		0	%		0	%
	Risk-free rate		1.4	%		1.7	%
	Expected life (years)		5.4			5.7
	Expected volatility		32.6	%		32.7	%

Stockholders_Equity_Tables

Stockholders Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes activities under option plans for the indicated periods:
			Options Outstanding
			Number of				Weighted			Weighted				Aggregate
			Shares				Average			Average				Intrinsic
							Exercise			Remaining Contractual				Value
							Price			Term
										(in years)
	Balances, December 31, 2014			3,670,000			$	1.2			8.3			$	1,109,200
	Options cancelled and retired			—				—
	Options exercised			—				—
	Options granted			—				—
	Balances, March 31, 2015			3,670,000				1.2			8.1				1,569,400
	Options vested and exercisable and expected to be vested and exercisable at March 31, 2015			3,380,000			$	1.2			8.1			$	1,569,400
	Options vested and exercisable at March 31, 2015			545,000			$	1.36			5.8			$	305,650
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table summarizes significant ranges of outstanding and exercisable options as of March 31, 2015:
					Options Outstanding, Vested and Exercisable
	Exercise Prices					Number			Weighted			Weighted				Number	Weighted Average Exercise Price Per Share
						Outstanding			Average			Average				Exercisable
									Remaining			Exercise
									Contractual			Price Per
									Life (in Years)			Share
	$	0.7				20,000			4.3			$	0.7			20,000	$	0.7
		0.83				1,500,000			7.1				0.83			375,000		0.83
		1.24				20,000			3.3				1.24			20,000		1.24
		1.37				2,000,000			9.4				1.37			—		1.37
		2.67				20,000			2.3				2.67			20,000		2.67
		2.95				90,000			1.45				2.95			90,000		2.95
		3.5				20,000			1.9				3.5			20,000		3.5
	Total					3,670,000			8.1			$	1.2			545,000	$	1.36
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	The following table summarizes restricted stock activities under the equity incentive plans for the indicated periods:
			Restricted Shares Outstanding
			Number of Shares				Weighted Average Grant Date Fair Value
	Balances, December 31, 2014			1,125,500			$	0.31
	Shares cancelled and forfeited			—				—
	Shares vested			—				—
	Shares granted			—				—
	Balances, March 31, 2015			1,125,000			$	0.31
Change in Non-Controlling Interest, Carrying amount	Balance at December 31, 2014		$	4,867
	Add: Income attributable to non-controlling interests			811
	Less: Cash distribution to non-controlling interests			(974	)
	Balance at March 31, 2015		$	4,704

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	The following table presents financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2015 (in thousands):
		Total Carrying Value in Consolidated Balance Sheet			Quoted prices			Significant		Significant
					in active			Other		Unobservable
					markets for			observable		inputs
					identical assets			inputs		(Level 3)
					or liabilities			(Level 2)
					(Level 1)
	Financial Assets:
	Warrant assets	$	1,406		$	—		$	—	$	1,406
	Available-for-sale securities		3,119			—			—		3,119
	Financial Liabilities:
	Warrant liability	$	586		$	—		$	—	$	586
	The following table presents financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2014 (in thousands):
		Total Carrying Value in Consolidated Balance Sheet			Quoted prices			Significant		Significant
					in active			other		unobservable
					markets for			observable		inputs
					identical assets			inputs		(Level 3)
					or liabilities			(Level 2)
					(Level 1)
	Financial Assets:
	Warrant assets	$	679		$	—		$	—	$	679
	Available-for-sale securities		3,119			—			—		3,119
	Financial Liabilities:
	Warrant liability	$	421		$	—		$	—	$	421
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The changes on the value of the warrant assets during the three months ended March 31, 2015, were as follows (in thousands):
	Balance at December 31, 2014	$	679
	Issuances		191
	Change in fair value		536
	Balance at March 31, 2015	$	1,406
Schedule of Assumptions Used [Table Text Block]	The following weighted average assumptions were used in the models to determine fair value:
		31-Mar-15			31-Dec-14
	Dividend rate		0	%		0	%
	Risk-free rate		1.4	%		1.8	%
	Expected life (years)		5.3			5.4
	Expected volatility		93.9	%		94.3	%
Fair Value, Liability Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The changes on the value of the warrant liability during the three months ended March 31, 2015, were as follows (in thousands):
	Balance at December 31, 2014	$	421
	Issuances		—
	Change in fair value		165
	Balance at March 31, 2015	$	586
Fair Value, by Balance Sheet Grouping [Table Text Block]	The following information is provided to help readers gain an understanding of the relationship between amounts reported in the accompanying consolidated financial statements and the related market or fair value. The disclosures include financial instruments and derivative financial instruments, other than investment in affiliates (in thousands):
	31-Mar-15	Carry			Fair			Level 1		Level 2		Level 3
		Value			Value
	Financial Assets
	Cash and cash equivalents	$	59,487		$	59,487		$	59,487	$	—	$	—
	Finance receivables		95,456			95,456			—		—		95,456
	Marketable investments		6,349			6,349			—		—		6,349
	Other assets		1,406			1,406			—		—		1,406
	Financial Liabilities
	Warrant liability	$	586		$	586		$	—	$	—	$	586
	31-Dec-14	Carry			Fair			Level 1		Level 2		Level 3
		Value			Value
	Financial Assets
	Cash and cash equivalents	$	58,728		$	58,728		$	58,728	$	—	$
	Finance receivables		93,347			93,347			—		—		93,347
	Marketable investments		4,849			4,849			—		—		4,849
	Other assets		679			679			—		—		679
	Financial Liabilities
	Warrant liability	$	421		$	421		$	—	$	—	$	421

Income_Taxes_Tables

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities		March 31,			December 31,
		2015			2014
	Deferred tax assets
	Credit carryforward	$	2,660		$	2,660
	Stock based compensation		470			470
	Other		271			271
	Net operating losses		145,007			146,513
	Gross deferred tax assets		148,408			149,914
	Valuation allowance		(129,808	)		(129,808	)
	Net deferred tax assets	$	18,600		$	20,106

Net_Income_per_Share_Details

Net Income per Share (Details) (USD $)	3 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Numerator:
Net income attributable to SWK Holdings Corporation Shareholders (in Dollars)	$2,256	$1,457
Denominator:
Weighted-average shares outstanding	129,964,000	41,462,000
Effect of dilutive securities	82,000	68,000
Weighted-average diluted shares	130,046,000	41,530,000
Basic earnings (loss) per share (in Dollars per share)	$0.02	$0.04
Diluted earnings (loss) per share (in Dollars per share)	$0.02	$0.04
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)	4,175,000	4,175,000

Finance_Receivables_Details

Finance Receivables (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Portfolio
Notes Receivable, Net	$95,456	$93,347
Life Science Term Loans [Member]
Portfolio
Notes Receivable, Net	82,645	80,450
Life Science Royalty Purchases [Member]
Portfolio
Notes Receivable, Net	$12,811	$12,897

Finance_Receivables_Details_Na

Finance Receivables (Details Narrative) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Receivables [Abstract]
Non-accrual loan	$6,650

Marketable_Investments_Details

Marketable Investments (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Marketable Investments Details
Fixed Income	$3,119	$3,119
Equity securities	3,230	1,730
Marketable investments	$6,349	$4,849

Marketable_Investments_Details1

Marketable Investments (Details 2) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Investment Holdings Reconciliation [Abstract]
Amortized Cost	$3,119	$3,119
Gross Unrealized Gains
Gross Unrealized Loss
Fair Value	$3,119	$3,119

Variable_Interest_Entities_Det

Variable Interest Entities (Details Narrative) (USD $)	3 Months Ended	12 Months Ended	1 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2012	Feb. 28, 2015
Note4VariableInterestEntitiesDetailsLineItems [Line Items]
Percent of Pharmaceutical Product's Cash Flow to be Received by the Limited Partnership				84.00%
Income (Loss) from Equity Method Investments	$1,551	$1,503
Comprehensive income attributable to non-controlling interests	811	801
Proceeds from Equity Method Investment, Dividends or Distributions	1,855	1,976
Payments to Noncontrolling Interests	974	1,055
Minimum Interest [Member]
Note4VariableInterestEntitiesDetailsLineItems [Line Items]
Percent of Pharmaceutical Product's Cash Flow to be Received by the Limited Partnership	39.00%
Non-controlling Interests in Consolidated Entities
Note4VariableInterestEntitiesDetailsLineItems [Line Items]
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures			7,000
Holmdel Pharmaceuticals LP [Member]
Note4VariableInterestEntitiesDetailsLineItems [Line Items]
Payments to Acquire Intangible Assets			13,000
Noncontrolling Interest, Ownership Percentage by Parent	70.00%
SWKHP Holdings LP [Member]
Note4VariableInterestEntitiesDetailsLineItems [Line Items]
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures			13,000
SWKHP Holdings GP [Member]
Note4VariableInterestEntitiesDetailsLineItems [Line Items]
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures			$6,000

Variable_Interest_Entities_Det1

Variable Interest Entities (Details) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Change in Investment Carrying Amount - Holmdel [Abstract]
Beginning Balance	$9,044
Add: Income from investments in unconsolidated entities	1,551	1,503
Less: Cash distribution on investments in unconsolidated entities	-1,855	-1,976
Ending Balance	$8,740	$9,044

Variable_Interest_Entities_Det2

Variable Interest Entities (Details 2) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Financial Statement Information - Holmdel [Abstract]
Assets	$11,900
Liabilities	2,400
Equity	9,500
Revenue	2,400	2,400
Expenses	400	600
Net income	$2,000	$1,800

Loan_Credit_Agreement_with_Rel1

Loan Credit Agreement with Related Party (Details Narrative) (USD $)	3 Months Ended	12 Months Ended	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014
Note5LoanCreditAgreementwithRelatedPartyDetailsLineItems [Line Items]
Warrants and Rights Outstanding	$586	$421
Unrealized Gain (Loss) on Derivatives	371	154
Interest Expense, Debt	381	189
Amortization of Financing Costs	381	35
Delayed Draw [Member]
Note5LoanCreditAgreementwithRelatedPartyDetailsLineItems [Line Items]
Debt Instrument, Basis Spread on Variable Rate	6.50%
Debt Instrument, Term	18 months
Line of Credit Facility, Maximum Borrowing Capacity	30,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)	1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Share)	$1.39
Amortization of Financing Costs	36
Delayed Draw [Member] | Due To Lender [Member]
Note5LoanCreditAgreementwithRelatedPartyDetailsLineItems [Line Items]
Interest Expense, Debt			153
Delayed Draw [Member] | Amount Available At Closing [Member]
Note5LoanCreditAgreementwithRelatedPartyDetailsLineItems [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$15,000

Loan_Credit_Agreement_with_Rel2

Loan Credit Agreement with Related Party (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Note5LoanCreditAgreementwithRelatedPartyDetailsValuationAssumptionsLineItems [Line Items]
Dividend rate	0.00%	0.00%
Risk-free rate	1.40%	1.80%
Expected life (years)	5 years 3 months 18 days	5 years 4 months 24 days
Expected volatility	93.90%	94.30%
Loan Credit Agreement [Member]
Note5LoanCreditAgreementwithRelatedPartyDetailsValuationAssumptionsLineItems [Line Items]
Dividend rate	0.00%	0.00%
Risk-free rate	1.40%	1.70%
Expected life (years)	5 years 4 months 24 days	5 years 8 months 12 days
Expected volatility	32.60%	32.70%

Stockholders_Equity_Details_Na

Stockholders' Equity (Details Narrative) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Director Compensation for non-employee directors	33,660
Share-based Goods and Nonemployee Services Transaction, Quantity of Securities Issued (in Shares)	10,000
Common stock issued in lieu of cash payments to non - employee director	32,595
Board compensation expense	$107

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	3 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Summary of Activities Under Option Plans [Abstract]
Balances - Number of shares	3,670,000	3,670,000
Balances - Weighted Average exercise price	$1.20	$1.20
Balances - Weighted average remaining contractual term	8 years 1 month 6 days	8 years 3 months 18 days
Balances - Aggregate intrinsic value	$1,569,400	$1,109,200
Options vested and exercisable and expected to be vested and exercisable at March 31, 2015		3,380,000
Options vested and exercisable and expected to be vested and exercisable at March 31, 2015		$1.20
Options vested and exercisable and expected to be vested and exercisable at March 31, 2015	8 years 1 month 6 days
Options vested and exercisable and expected to be vested and exercisable at March 31, 2015		1,569,400
Options vested and exercisable at end of period		545,000
Options vested and exercisable at end of period		$1.36
Options vested and exercisable at end of period	5 years 9 months 18 days
Options vested and exercisable at end of period		$305,650

Stockholders_Equity_Details_2

Stockholders' Equity (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Prices	$1.20	$1.20
Weighted Average Exercise Price Per Share	$1.20	$1.20
Seventy cents [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Prices	$0.70
Number Outstanding, Vested and Exercisable (in Shares)	20,000
Weighted Average Remaining Contractual Life (In Years)	4 years 3 months 18 days
Weighted Average Exercise Price Per Share	$0.70
Number Exercisable (in Shares)	20,000
Weighted Average Exercise Price Per Share	$0.70
Eighty Three Cents [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Prices	$0.83
Number Outstanding, Vested and Exercisable (in Shares)	1,500,000
Weighted Average Remaining Contractual Life (In Years)	7 years 1 month 6 days
Weighted Average Exercise Price Per Share	$0.83
Number Exercisable (in Shares)	375,000
Weighted Average Exercise Price Per Share	$0.83
One Dollar Twenty Four Cents [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Prices	$1.24
Number Outstanding, Vested and Exercisable (in Shares)	20,000
Weighted Average Remaining Contractual Life (In Years)	3 years 3 months 18 days
Weighted Average Exercise Price Per Share	$1.24
Number Exercisable (in Shares)	20,000
Weighted Average Exercise Price Per Share	$1.24
One Dollar Eighty Three Cents [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Prices	$1.37
Number Outstanding, Vested and Exercisable (in Shares)	2,000,000
Weighted Average Remaining Contractual Life (In Years)	9 years 4 months 24 days
Weighted Average Exercise Price Per Share	$1.37
Weighted Average Exercise Price Per Share	$1.37
Two Dollars Sixty Seven Cents [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Prices	$2.67
Number Outstanding, Vested and Exercisable (in Shares)	20,000
Weighted Average Remaining Contractual Life (In Years)	2 years 3 months 18 days
Weighted Average Exercise Price Per Share	$2.67
Number Exercisable (in Shares)	20,000
Weighted Average Exercise Price Per Share	$2.67
Two Ninety Five [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Prices	$2.95
Number Outstanding, Vested and Exercisable (in Shares)	90,000
Weighted Average Remaining Contractual Life (In Years)	1 year 5 months 12 days
Weighted Average Exercise Price Per Share	$2.95
Number Exercisable (in Shares)	90,000
Weighted Average Exercise Price Per Share	$2.95
Three Fifty [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Prices	$3.50
Number Outstanding, Vested and Exercisable (in Shares)	20,000
Weighted Average Remaining Contractual Life (In Years)	1 year 10 months 24 days
Weighted Average Exercise Price Per Share	$3.50
Number Exercisable (in Shares)	20,000
Weighted Average Exercise Price Per Share	$3.50
Total [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Prices	$1.20
Number Outstanding, Vested and Exercisable (in Shares)	3,670,000
Weighted Average Remaining Contractual Life (In Years)	8 years 1 month 6 days
Weighted Average Exercise Price Per Share	$1.20
Number Exercisable (in Shares)	545,000
Weighted Average Exercise Price Per Share	$1.36

Stockholders_Equity_Details_3

Stockholders' Equity (Details 3) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Note6StockholdersEquityDetailsRestrictedStockActivityLineItems [Line Items]
Balances, Number of Shares	1,125,000
Shares cancelled and forfeited
Shares vested
Shares granted
Balances, Weighted Average Grant Date Fair Value (per share)	$0.31
Shares cancelled and forfeited (per share)
Shares vested (per share)
Shares granted (per share)
Restricted Stock [Member]
Note6StockholdersEquityDetailsRestrictedStockActivityLineItems [Line Items]
Balances, Weighted Average Grant Date Fair Value (per share)		$0.31

Stockholders_Equity_Details_4

Stockholders' Equity (Details 4) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Changes in Carrying Amount of Non-Controlling Interest [Abstract]
Beginning Balance	$4,867
Add: Income attributable to non-controlling interests	811	801
Less: Cash distribution to non-controlling interests	-974
Ending Balance	$4,704	$4,867

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Financial Assets:
Tribute warrant	$1,406	$679
Available-for-sale securities	3,119	3,119
Financial Liabilities:
Warrant liability	586	421
Fair Value, Inputs, Level 3 [Member]
Financial Assets:
Available-for-sale securities	3,119	3,119
Tribute Warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Financial Assets:
Tribute warrant	1,406	679
Financial Liabilities:
Warrant liability	586	421
Tribute Warrant [Member] | Marketable Securities [Member]
Financial Assets:
Tribute warrant	1,406	679
Financial Liabilities:
Warrant liability	$586	$421

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 2) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value - December 31	$679
Fair value - December 31	1,406	679
Fair value - December 31	421
Change in fair value of warrants	-371	-154
Fair value - December 31	586	421
Tribute Warrant [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value - December 31	679
Issuances	191
Change in fair value	536
Fair value - December 31	1,406
Warrant Liability [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value - December 31	421
Issuances
Change in fair value of warrants	165
Fair value - December 31	$586

Fair_Value_Measurements_Detail2

Fair Value Measurements (Details 3)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Fair Value Measurements Details 3
Dividend rate	0.00%	0.00%
Risk-free rate	1.40%	1.80%
Expected life (years)	5 years 3 months 18 days	5 years 4 months 24 days
Expected volatility	93.90%	94.30%

Fair_Value_Measurements_Detail3

Fair Value Measurements (Details 4) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Financial Assets
Cash and cash equivalents	$59,487	$58,728	$7,664
Cash and cash equivalents at fair value	59,487	58,728
Finance receivables	95,456	93,347
Finance receivables at fair value	95,456	93,347
Marketable investments	6,349	4,849
Marketable investments at fair value	6,349	4,849
Other assets	1,406	679
Other Assets at fair value	1,406	679
Financial Liabilities
Warrant liability	586	421
Gross liability at fair value	586	421
Fair Value, Inputs, Level 1 [Member]
Financial Assets
Cash and cash equivalents at fair value	59,487	58,728
Fair Value, Inputs, Level 3 [Member]
Financial Assets
Finance receivables at fair value	95,456	93,347
Marketable investments at fair value	6,349	4,849
Other Assets at fair value	1,406	679
Financial Liabilities
Gross liability at fair value	$586	$421

Income_Taxes_Details

Income Taxes (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Deferred tax assets
Credit carryforward	$2,660	$2,660
Stock based compensation	470	470
Other	271	271
Net operating losses	145,007	146,513
Gross deferred tax assets	148,408	149,914
Valuation allowance	-129,808	-129,808
Net deferred tax assets	$18,600	$20,106

Income_Taxes_Details_Narrative

Income Taxes (Details Narrative) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Income Taxes Details Narrative
Net operating loss carryforwards resulting from tax deductions upon the exercise of employee stock options	$1,900
Net operating loss carryforwards for federal income tax		$421,000

Subsequent_Events_Details_Narr

Subsequent Events (Details Narrative) (USD $)	0 Months Ended	1 Months Ended
In Thousands, except Share data, unless otherwise specified	7-May-15	Apr. 30, 2015	Mar. 31, 2015	Apr. 06, 2015
Debt Instrument, Face Amount			$6,650
Subsequent Event [Member]
Debt Instrument, Face Amount		12,500		2,000
Commitment Assigned to the Company	12,000	10,000
Class of Warrant or Right, Outstanding (in Shares)		8,152,174		1,351,351
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Share)		$0.46
Amount funded by Company				1,000
Amount funded by unaffiliated third party				$1,000